Takeda’s zasocitinib proves ‘top-notch’ for difficult-to-treat psoriasis in phase 3 update
Takeda has unveiled more data from its phase 3 trials of zasocitinib, demonstrating that the once-daily pill was able to clear or almost clear scalp psoriasis in 75% of patients.
Read the full articleYou might also wanna read
Takeda’s Zasocitinib Demonstrates Consistent, High Rates of Skin Clearance Across the Body, Including Hard-to-Treat and High-Impact Sites, in Phase 3 Psoriasis Studies
On average, about 75% of patients with scalp psoriasis treated with zasocitinib achieved clear or almost clear skin at week 16 Approximately
Icotrokinra Maintains Psoriasis Skin Clearance Through 52 Weeks
One-year Phase III data show icotrokinra delivered durable skin clearance and symptom improvement in adults with moderate-to-severe plaque p
A Phase 3 Trial of Upadacitinib for Giant-Cell Arteritis
Dr. Shuvro Roy and Dr. Daniel Blockmans discuss the efficacy and safety of upadacitinib as a treatment option for giant-cell arteritis. Show
Abrocitinib Boosts Skin Clearance and Itch Relief in AD
Abrocitinib can help achieve minimal disease activity in patients with atopic dermatitis irrespective of previous exposure to dupilumab, a p
The Safety and Efficacy of Upadacitinib in Refractory Autoimmune Related Cholangitis and Atopic Dermatitis With Moderate to Severe Itching
Conditions : Primary Biliary Cholangitis (PBC); Primary Sclerosing Cholangitis (PSC); Atopic Dermatitis (AD) Interventions : Drug: Upadaciti
A Phase I Study of SSGJ-716 in Healthy Adults and Participants With Moderate-to-Severe Atopic Dermatitis
Conditions : AD Interventions : Drug: SSGJ-716; Drug: Placebo Sponsors : Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. Recruiting
Comments
Sign in to join the conversation.
No comments yet. Be the first.